title: Aldosterone blockade in metabolic syndrome: hitting the target or still missing some links?
authors.affiliation: Department of Cardiology, Liverpool Hospital, Liverpool, NSW 1871, Australia. d.leung@unsw.edu.au
authors.forename: Dominic Y
authors.initials: DY
authors.lastname: Leung
mesh_terms: D005260:Female; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy*; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy*; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D009206:Myocardium / Q000378:metabolism*; D010446:Peptide Fragments / Q000097:blood*; D011347:Procollagen / Q000097:blood*; D013148:Spironolactone / Q000627:therapeutic use*; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy*; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; C042813:procollagen type I carboxy terminal peptide; D013148:Spironolactone